This invention relates to compounds of Formula (I) and the use of compounds of Formula (I) as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems.
This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:
本发明涉及I式化合物及其在治疗中枢和周围神经系统神经元疾病中作为神经保护剂的应用。I式:
IMIDAZO [2,1,-b]-1,3,4-THIADIAZOLE SULFONAMIDES
申请人:JAQUITH James B.
公开号:US20090042953A1
公开(公告)日:2009-02-12
This invention relates to compounds of Formula I and the use of compounds of Formula I as neuroprotective agents in the treatment of neuronal disorders of the central and peripheral nervous systems. Formula I:
本发明涉及公式I化合物及其作为神经保护剂用于治疗中枢和外周神经系统的神经元疾病的用途。公式I:
Khazi, Imtiyaz A. M.; Mahajanshetti, Chanbasappa S.; Gadad, Andanappa K., Arzneimittel-Forschung/Drug Research, 1996, vol. 46, # 10, p. 949 - 952
作者:Khazi, Imtiyaz A. M.、Mahajanshetti, Chanbasappa S.、Gadad, Andanappa K.、Tarnalli, Ashok D.、Sultanpur, Chandrashekhar M.
DOI:——
日期:——
Synthesis and antibacterial activity of some 5-guanylhydrazone/thiocyanato-6-arylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamide derivatives†
作者:A Gadad
DOI:10.1016/s0223-5234(00)00166-5
日期:2000.9
6-Arylimidazo[2,1-b]-1,3,4-thiadiazole-2-sulfonamides 3 on Vilsmeier-Haak reaction produced 5-formyl-6-arylimidazo[2, 1-b]1,3,3-thiadiazole-2-[N-(dimethylaminomethino)]sulfonamides 4, while 3 on treatment with potassium thiocyanate in the presence of bromine in acetic acid produced 5-thiocyanato-2-sulfonamides 6. Interaction of 4 with aminoguanidine hydrochloride in ethanol produced the corresponding 5-guanylhydrazone derivatives 5. Compounds 5 and 6 showed a high degree of antibacterial activity against both Escherichia coli and Staphylococcus aureus comparable to that of sulfamethoxazole and Norfloxacin. However, they were found to show moderate activity against Salmonella typhi, Pseudomonas aeruginosa and Pneumococci. (C) 2000 Editions scientifiques et medicales Elsevier SAS.